Novo Nordisk agrees to acquire Corvidia Therapeutics for $2.1bn

This article was originally published here

Under the terms of the agreement, the Danish pharmaceutical firm will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of $725m in cash. The company

The post Novo Nordisk agrees to acquire Corvidia Therapeutics for $2.1bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply